Breast Care最新文献

{"title":"The Risk of Cardiovascular Disease following Aromatase Inhibitor Therapy for Breast Cancer in Postmenopausal Women: A Systematic Review and Meta-Analysis.","authors":"Elijah Berbari, Arsalan Anees, Rajneesh Kaur, Femi E Ayeni, Senarath Edirimanne","doi":"10.1159/000546089","DOIUrl":"10.1159/000546089","url":null,"abstract":"<p><strong>Background: </strong>More women are recovering and living longer lives due to advancement in breast cancer therapies. Aromatase inhibitors (AIs) are one form of endocrine therapy for breast cancer that may have an impact on the risk of developing cardiovascular diseases later in life. This study investigated whether AI therapy for breast cancer in postmenopausal women increases the risk of developing cardiovascular disease in comparison with tamoxifen therapy or no hormonal therapy.</p><p><strong>Methods: </strong>Comparisons were made between tamoxifen and no hormonal therapy using PRISMA guidelines. We searched publicly available databases for studies including postmenopausal women who underwent AI therapy for breast cancer investigating the risk ratio of specific cardiovascular outcomes and cardiovascular death.</p><p><strong>Results: </strong>There was a significant increase in the risk of ischaemic heart disease (RR 1.59, 95% CI: 1.25-2.02, <i>p</i> < 0.05), myocardial infarction (RR 1.50, 95% CI: 1.13-1.99, <i>p</i> < 0.05), heart failure (RR 1.63, 95% CI: 1.14-2.32, <i>p</i> < 0.05), and other cardiovascular events (RR 1.26, 95% CI: 1.12-1.40, <i>p</i> < 0.05) in the AI group when compared to tamoxifen. However, there was a significant decrease in the risk of myocardial infarction (RR 0.77, 95% CI: 0.65-0.90, <i>p</i> < 0.05) in the AI group when compared to no hormonal treatment.</p><p><strong>Conclusion: </strong>There is an increased risk of cardiovascular disease for AI therapy in comparison to tamoxifen therapy. However, further research is needed to establish the cardiovascular risk of AIs when compared to no hormonal therapy. Prognosis and survival of patients should be an important consideration in choosing between tamoxifen and AI therapy among patients receiving treatment for breast cancer. Regular monitoring is essential to facilitate personalized approaches aimed at mitigating the risk of cardiovascular toxicity.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12259065/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Validation of a Predictive Model for Sentinel Lymph Node Biopsy Exemption in Ductal Carcinoma in situ Patients.","authors":"Zhihong Xu, Dan Tao, Qihua Jiang, Wensong Wei, Qian Ma","doi":"10.1159/000546885","DOIUrl":"10.1159/000546885","url":null,"abstract":"<p><strong>Introduction: </strong>There is no uniform standard on whether total mastectomy for ductal carcinoma in situ (DCIS) can exempt sentinel lymph node biopsy (SLNB). This study attempts to find the risk factors for the underestimation of DCIS pathology and establish the corresponding prediction model to screen suitable DCIS patients for exemption from SLNB.</p><p><strong>Methods: </strong>A total of 826 patients with DCIS met the inclusion criteria. Logistic regression identified lesion size, Ki67, estrogen receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, histological grade, and diagnostic method as independent predictors of pathological underestimation (<i>p</i> < 0.05). Based on these variables, a predictive model was developed: <i>p</i> = 0.354 × lesion size + 0.017 × Ki67 + 1.186 × ER - 2.501 × diagnosis method (1) - 1.575 × diagnosis method (2) - 0.050 × HER2 (1) - 1.578 × HER2 (2) + 1.160 × grade (1) + 1.497 × grade (2) - 2.418 (if age <50) - 0.156 × 1 (if age >50). The model showed good performance with a sensitivity of 79.2%, specificity of 73.8%, and overall accuracy of 76.2%. The area under the ROC curve (AUC) was 0.856 (95% confidence interval: 0.831-0.881, <i>p</i> < 0.001). Subgroup analyses indicated that age, presence of mass, ER, HER2, tumor grade, and histological grade significantly affected model performance (AUC = 0.787; sensitivity = 0.695; specificity = 0.753). Stratified analysis showed higher sensitivity in patients <50 years (0.840 vs. 0.656) and higher AUC in ER-positive cases (0.865). In HER2-based analysis, only the presence of a mass remained significant. Mass-based analysis revealed all variables except age were significant, with a higher AUC in patients without a mass (0.784 vs. 0.727).</p><p><strong>Conclusion: </strong>This study developed a predictive model based on lesion size, Ki67, ER status, HER2 status, histological grade, and diagnostic method to assess the risk of pathological underestimation in DCIS. The model demonstrated good predictive performance (AUC = 0.856) with high sensitivity and specificity, indicating its potential clinical utility. Subgroup analyses revealed that factors such as age, presence of a mass, and ER status influenced model performance, with particularly better accuracy observed in patients under 50 and those with ER-positive tumors. This model may serve as a useful tool to support clinical decision-making, especially in preoperative evaluation of invasive potential in DCIS patients.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12274069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using Virtual Therapy for Lymphedema and Disability Post-Mastectomy: Meta-Analysis with Systematic Review.","authors":"Islam Bani Mohammad, Muayyad Ahmad","doi":"10.1159/000546605","DOIUrl":"10.1159/000546605","url":null,"abstract":"<p><strong>Introduction: </strong>This review and meta-analysis aimed to examine the effects of virtual reality (VR) therapy on lymphedema and disability management in post-mastectomy breast cancer patients, following PRISMA protocol.</p><p><strong>Methods: </strong>Databases were extensively searched, including Wiley Online Library, ProQuest, MEDLINE, CINAHL, Google Scholar, Science Direct, and SAGE Journals, covering studies from January 2016 to August 2024. This review was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.</p><p><strong>Results: </strong>Nine studies met the inclusion criteria. The findings indicate VR therapy effectively reduces post-mastectomy lymphedema and aids upper limb disability rehabilitation, with sessions lasting 10-50 min. The meta-analysis statistics showed a significant decrease in disability, measured by the disability of the arm, shoulder, and hand (DASH) scale, with an effect size of -0.931 (<i>Z</i> score = -2.713, <i>p</i> = 0.007) and a 95% confidence interval of -1.604 to -0.259.</p><p><strong>Conclusions: </strong>These results strongly support VR's efficacy in managing lymphedema and disability, recommending its integration into routine care at oncology centers and hospitals. This article explains compelling evidence that VR is effective in helping patients with lymphedema manage their disabilities. Rehabilitation programs using VR after mastectomy should be incorporated into the daily care in oncology centers and hospitals. Further interventional studies are needed to strengthen evidence and refine VRs clinical application.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144607370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Safety of Elacestrant in Patients with Breast Cancer: Insights from Food and Drug Administration Adverse Event Reporting System Database Analysis.","authors":"Tailong Lv, Wenkai Bao, Shouqiang Chen","doi":"10.1159/000546678","DOIUrl":"10.1159/000546678","url":null,"abstract":"<p><strong>Introduction: </strong>This study aims to evaluate the safety profile of elacestrant in real-world settings using data from the FDA adverse event (AE) reporting system (FAERS) database, offering insights to inform clinical use.</p><p><strong>Methods: </strong>Data are collected from the FAERS database spanning the first quarter of 2023 through the third quarter of 2024. AEs associated with elacestrant are identified using reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multinomial gamma Poisson shrinkageanalyses. The temporal distribution of AEs is assessed using Weibull distribution to evaluate the drug's safety comprehensively.</p><p><strong>Results: </strong>Reports of 6,476 AEs with elacestrant as the primary suspect drug are identified, spanning 27 organ systems. A total of 53 preferred terms signal are detected across four algorithms, including known adverse reactions such as nausea, vomiting, fatigue, elevated blood cholesterol, and musculoskeletal pain. Potential new AEs, including pathological fractures, gastroesophageal reflux disease, hypokalemia, lymphedema, and dehydration, are also identified. The median onset time for elacestrant-related AEs is 44 days, with most events occurring within the first month of treatment.</p><p><strong>Conclusion: </strong>This study offers real-world insights into elacestrant usage, confirming known adverse reactions and identifying previously unreported events. These findings provide valuable guidance for clinicians in minimizing drug risks during treatment.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12215442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Local Recurrence Outcomes between Breast Conservation Therapy and Mastectomy for the Treatment of Breast Cancer among Young Women: A Systematic Review and Meta-Analysis.","authors":"Yiming Sun, Feng Zhang, Qi Guo, Xiaowen Ma","doi":"10.1159/000546783","DOIUrl":"10.1159/000546783","url":null,"abstract":"<p><strong>Background: </strong>Recent clinical trials comparing local recurrence rates in young breast cancer (BC) patients after breast-conserving therapy (BCT) versus mastectomy are limited. The local recurrence (LR) rate in young BC patients is notably higher than in other age groups, whether the recurrence rates after the two surgical options are comparable remains unclear. This meta-analysis aimed to assess the safety of BCT and mastectomy for young age BC patients by comparing LR rates between the two procedures.</p><p><strong>Methods: </strong>We conducted a systematic search of four electronic databases (Medline, PubMed, Cochrane Library, and Web of Science) for relevant studies comparing LR rates in BC patients aged 40 years or younger who were treated with BCT or mastectomy. Studies that met the inclusion criteria were synthesized using a random-effects model, with a primary focus on LR rates. Sensitivity analyses and meta-regression were performed to evaluate bias and heterogeneity, ensuring a thorough assessment of the available evidence.</p><p><strong>Results: </strong>Among the 2,936 studies screened, 10 studies encompassing 9,215 patients were included, with 5,236 undergoing BCT and 5,803 undergoing mastectomy. The summary odds ratio (OR) indicated a significantly greater risk of LR for BCT compared to mastectomy among young BC patients (OR = 1.48; 95% CI: 1.12-1.96). In subgroup analysis, the BCT group exhibited a higher 5-year LR rate (OR = 1.67; 95% CI: 1.13-2.46) compared to the mastectomy group. This trend persisted across tumor stages, with the BCT group showing an increased LR risk in both the T1-2 (OR = 1.84; 95% CI: 1.44-2.36) and T1-4 (OR = 1.74, 95% CI: 1.50-2.03) stages. Nodal status analysis indicated a higher LR risk for BCT in the N0-1 (OR = 2.549, 95% CI: 1.79-3.46) stages. Among very young women (aged ≤35), the difference in LR rates between BCT and mastectomy was even more pronounced (OR = 2.04, 95% CI: 1.47-2.82).</p><p><strong>Conclusion: </strong>Our meta-analysis found that young BC patients undergoing BCT had a significantly higher risk of LR, with a 48% increased risk compared to those who underwent mastectomy (OR = 1.48; 95% CI: 1.12-1.96). This difference was even more pronounced in patients aged 35 years or younger. While the elevated LR risk with BCT in young patients is well documented, individualized treatment planning should weigh this against potential survival advantages and quality-of-life preservation.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12234014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144590513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Patient Satisfaction and Quality of Life Using the BREAST-Q Questionnaire in Oncoplastic Breast-Conserving Surgery Techniques for Centrally Located Breast Cancer.","authors":"Halit Özgül, Gülşah Çelik, Remzi Can Çakir, Ömer Çelik, Ali Çelik","doi":"10.1159/000544114","DOIUrl":"10.1159/000544114","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to retrospectively compare the impact of level-2 oncoplastic techniques - doughnut, lateral, vertical, and racket mastopexy - on patient satisfaction and quality of life in centrally located breast cancer surgery, using the BREAST-Q questionnaire.</p><p><strong>Methods: </strong>This study included patients aged 18-65 who underwent oncoplastic surgery for centrally located breast tumors at a teaching hospital between January 2021 and August 2024. The BREAST-Q questionnaire, which assesses satisfaction with the breast, psychosocial well-being, and sexual health, was administered at least 3 months post-surgery and radiotherapy. Demographic and clinical data were collected from the patient records.</p><p><strong>Results: </strong>Among the 142 patients included in the study, 90 underwent doughnut mastopexy, while 52 received other techniques. The BREAST-Q scores indicated higher satisfaction with breasts (92.28%), psychosocial well-being (87.41%), and sexual well-being (86.39%) in the doughnut mastopexy group compared to the other techniques (<i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>Doughnut mastopexy yielded better outcomes than other techniques, likely because of minimal scarring, reduced need for contralateral procedures, and improved aesthetic results. These findings suggest that this technique offers superior patient satisfaction for centrally located breast tumors.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 3","pages":"145-153"},"PeriodicalIF":2.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180785/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pyoderma Gangrenosum of the Breast: A Diagnostic Challenge.","authors":"Joaquim Marcoval, Clara Muntaner-Virgili, Júlia Boronat-Cucarull, Marta Gangonells-Dols, Alvaro Lagos-Tapia","doi":"10.1159/000544905","DOIUrl":"10.1159/000544905","url":null,"abstract":"<p><strong>Introduction: </strong>Pyoderma gangrenosum (PG) is a rare, noninfectious neutrophilic dermatosis usually located in the legs. PG of the breast is infrequent and may be a diagnostic challenge. Our objective was to review our patients with breast PG in order to analyse their clinical features.</p><p><strong>Methods: </strong>Patients diagnosed with PG involving the breast in Bellvitge University Hospital (Barcelona, Spain) between 2000 and 2023 were included in the study. Medical charts were retrospectively reviewed to obtain clinical data.</p><p><strong>Results: </strong>Ten patients were diagnosed with breast PG (10 women aged between 30 and 63 years, median 49.5). Evolution time at diagnosis ranged between 4 days and 7 months. In all cases, PG lesions were painful. All patients presented ulcerated lesions. In 2 cases, nodular abscess-like lesions and cribriform scars were also observed. The nipple was involved in 4 cases. Two patients had underlying diseases recognized as frequently associated with PG (ulcerative colitis and rheumatoid arthritis). Seven patients had a previous breast surgery that was considered related to PG (removal of breast carcinoma with breast reconstruction in 6 cases and breast reduction in one). The diagnosis of postsurgical breast PG was delayed in 6 patients by between 3 and 7 months. One patent developed radiation therapy induced pathergy after healing of postsurgical PG.</p><p><strong>Conclusion: </strong>The most common triggering factor for breast PG in our study was reconstruction following surgery for breast carcinoma. Medical professionals who treat breast diseases should be aware of this disease in order to lessen diagnostic delay.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 3","pages":"182-188"},"PeriodicalIF":2.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three-Fraction External Beam Radiotherapy in Patients with Early Breast Cancer.","authors":"Budhi Singh Yadav, Habeeb Kudukkil Appakattu Kuzhi, Divya Dahiya, Monsu Rathod, Arun Oinam Singh, Gaganpreet Singh","doi":"10.1159/000543855","DOIUrl":"10.1159/000543855","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with early breast cancer (EBC) can be treated with accelerated partial breast irradiation (APBI). The objective of this study was to determine if a three-fraction APBI schedule is feasible for these patients.</p><p><strong>Methods: </strong>This single-institutional, phase 2 study included patients with age ≥45 years, tumor size <3.5 cm, negative nodes, negative surgical margins, and unicentric tumors. Patients were treated with 3D-CRT technique with a dose of 22.5 Gy in 3 fractions on 3 consecutive days. The primary end point of the study was cosmesis as assessed by physicians at 3 years. Secondary end points were cosmesis as assessed by patients, dosimetry, acute and late toxicities, disease-free and overall survival.</p><p><strong>Results: </strong>From October 2019 to October 2022, 49 patients were treated. Mean age of the patients was 55 years (range 40-75). At 3 years, physician- and patient-reported cosmetic results were excellent/good/fair in 33 (67%)/14 (29%)/2 (4%) of patients and in 29 (59%)/16 (33%)/4 (8%) of patients, respectively. Acute dermatitis grades 1 and 2 were observed in 14 (29%) and 3 (6%) of patients, respectively. At 6 months, breast edema, skin induration, subcutaneous fibrosis, pain, and pigmentation were observed in 3 (6%), 6 (12%), 3 (6%), 2 (4%), and 8 (16%) of patients, respectively. At 3 years, 1 (2%) patient had mild pain; no breast edema, skin induration, subcutaneous fibrosis, or pigmentation was observed. At a median follow-up of 39 months (range 24-60), there were no local/regional recurrences. One patient developed distant metastases in the bones, liver, and lungs at 46 months. All patients were alive at last follow-up.</p><p><strong>Conclusion: </strong>In patients with EBC, three-fraction APBI is feasible. Physician- and patient-reported cosmesis was excellent/good in 96% and 92% of patients, respectively. Late effects were only grade 1.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 3","pages":"154-162"},"PeriodicalIF":2.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180790/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Axillary Surgical Management in Breast Cancer Patients after Neoadjuvant Systemic Therapy: A Delphi Study.","authors":"Michael Stanczyk, Ayat ElSherif, Tiffany Cheung, Alicia Fanning, Amanda Mendiola, Andrew Fenton, Debra Pratt, Mary Murray, Stephanie Valente, Zahraa Al-Hilli, Julie E Lang","doi":"10.1159/000546267","DOIUrl":"10.1159/000546267","url":null,"abstract":"<p><strong>Introduction: </strong>The use of sentinel lymph node biopsy in post-neoadjuvant systemic therapy (NST) patients is an evolving practice for breast cancer surgeons. Our study sought to determine if controversial areas in the treatment of post-NST breast cancer patients had consensus among our panel of breast cancer surgeons at a single institution. Our group updated our care path for the surgical management of breast cancer in November 2022. We aimed to see the influence of the care path update on reaching consensus for the management of the axilla post-NST.</p><p><strong>Methods: </strong>We performed two rounds of a modified eDelphi in 2021 and 2024 with a panel of 13 and 8 breast cancer surgeons, respectively, to evaluate a shift in expert opinion regarding axillary management in that period. Concordant responses were defined as greater than 75%.</p><p><strong>Results: </strong>The panel reached consensus on sentinel lymph node biopsy for initially clinically node-negative patients, management of extracapsular extension, similar treatment of post-neoadjuvant chemotherapy patients and post-neoadjuvant endocrine therapy patients, and the value of dual tracer, MRI, and SAVI Scout. There was lack of consensus among the panel on management of micrometastases, management of isolated tumor cells, management of initially node-positive patients that downgraded to node-negative, use of lymphovenous bypass, and use of axillary radiation in post-neoadjuvant chemotherapy patients. Consensus was reached in 45% of questions in 2021 and 47% in 2023.</p><p><strong>Conclusion: </strong>Despite having an institutional care path, our expert panel reached consensus regarding contemporary issues in breast surgery less than 50% of the time. Our study advocates for further research in the management of topics that did not reach consensus.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"1-9"},"PeriodicalIF":2.0,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12201954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"St. Gallen/Vienna 2025 Summary of Key Messages on Therapy in Early Breast Cancer from the 2025 St. Gallen International Breast Cancer Conference.","authors":"Nina Ditsch, Michael Gnant, Christoph Thomssen, Nadia Harbeck","doi":"10.1159/000546080","DOIUrl":"10.1159/000546080","url":null,"abstract":"<p><strong>Background: </strong>In 2025, the St. Gallen Conference was held from March 12th-15th, with the largest attendance since the pandemic and more than 3,000 participants from over 100 countries.</p><p><strong>Summary: </strong>The conference chairs professionally guided through the program on Early Breast Cancer, featuring abstracts submitted from all over the world. In addition, Prof. Dr. Herold J. Burstein (USA) led the panel through the difficult topics of local and systemic treatment modalities in an excellent, clearly structured and engaging way. Almost 80 experts from all continents and more than 30 nations formed the panel and summarized the current literature in excellent presentations and discussions.</p><p><strong>Key messages: </strong>Final voting covered the topics of genetic testing, DCIS, breast and axillary surgery, radiation therapy, systemic treatment based on subtypes, treatment of the elderly, therapy of local-regional recurrence and oligometastatic breast cancer.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"1-10"},"PeriodicalIF":2.0,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180904/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144367920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}